ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Gyre Therapeutics Inc

Gyre Therapeutics Inc (GYRE)

9.72
0.01
( 0.10% )
Updated: 10:26:21

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
9.72
Bid
9.70
Ask
9.89
Volume
20,398
9.69 Day's Range 9.975
8.26 52 Week Range 19.00
Market Cap
Previous Close
9.71
Open
9.79
Last Trade
1
@
9.71
Last Trade Time
10:27:59
Financial Volume
$ 199,342
VWAP
9.7726
Average Volume (3m)
111,638
Shares Outstanding
93,521,434
Dividend Yield
-
PE Ratio
-9.78
Earnings Per Share (EPS)
-0.99
Revenue
113.45M
Net Profit
-92.93M

About Gyre Therapeutics Inc

Gyre Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in the research, development, manufacturing, and commercialization of drugs for organ fibrosis. It is primarily focused on the development and commercialization of F351 (Hydronidone) for the treatment of Nonalc... Gyre Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in the research, development, manufacturing, and commercialization of drugs for organ fibrosis. It is primarily focused on the development and commercialization of F351 (Hydronidone) for the treatment of Nonalcoholic Steatohepatitis Treatment (NASH)-associated fibrosis. The Company is also advancing a diverse pipeline in the China through its indirect controlling interest in Gyre Pharmaceuticals, including ETUARY therapeutic expansions, F573, F528, and F230. The Company operates through two segments: Gyre Pharmaceuticals, and Gyre after the Contributions. The Gyre Pharmaceuticals has one major commercial drug product, ETUARY, and several product candidates in pre-clinical and clinical development. Gyre is a biopharmaceutical company focused on the development and commercialization of F351 for the treatment of non-alcoholic steatohepatitis-associated liver fibrosis in the United States. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Wilmington, Delaware, USA
Founded
-
Gyre Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker GYRE. The last closing price for Gyre Therapeutics was $9.71. Over the last year, Gyre Therapeutics shares have traded in a share price range of $ 8.26 to $ 19.00.

Gyre Therapeutics currently has 93,521,434 shares outstanding. The market capitalization of Gyre Therapeutics is $908.09 million. Gyre Therapeutics has a price to earnings ratio (PE ratio) of -9.78.

GYRE Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-2.38-19.669421487612.112.42218.4854010529.64968532CS
4-1.83-15.844155844211.5513.758.48517058710.25021555CS
12-3.13-24.357976653712.8513.758.48511163810.60852205CS
26-3.79-28.053293856413.51198.4859357011.32224356CS
52-7.4-43.224299065417.12198.267998312.19718811CS
1562.7238.8571428571730.45.888631514.54406787CS
2602.7238.8571428571730.45.888631514.54406787CS

GYRE - Frequently Asked Questions (FAQ)

What is the current Gyre Therapeutics share price?
The current share price of Gyre Therapeutics is $ 9.72
How many Gyre Therapeutics shares are in issue?
Gyre Therapeutics has 93,521,434 shares in issue
What is the market cap of Gyre Therapeutics?
The market capitalisation of Gyre Therapeutics is USD 908.09M
What is the 1 year trading range for Gyre Therapeutics share price?
Gyre Therapeutics has traded in the range of $ 8.26 to $ 19.00 during the past year
What is the PE ratio of Gyre Therapeutics?
The price to earnings ratio of Gyre Therapeutics is -9.78
What is the cash to sales ratio of Gyre Therapeutics?
The cash to sales ratio of Gyre Therapeutics is 8.01
What is the reporting currency for Gyre Therapeutics?
Gyre Therapeutics reports financial results in USD
What is the latest annual turnover for Gyre Therapeutics?
The latest annual turnover of Gyre Therapeutics is USD 113.45M
What is the latest annual profit for Gyre Therapeutics?
The latest annual profit of Gyre Therapeutics is USD -92.93M
What is the registered address of Gyre Therapeutics?
The registered address for Gyre Therapeutics is 251 LITTLE FALLS DRIVE, NEW CASTLE, WILMINGTON, DELAWARE, 19808
What is the Gyre Therapeutics website address?
The website address for Gyre Therapeutics is www.gyretx.com
Which industry sector does Gyre Therapeutics operate in?
Gyre Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
IMTEIntergrated Media Technology Ltd
$ 1.2407
(129.80%)
44.82M
MLGOMicroAlgo Inc
$ 5.5698
(121.02%)
89.93M
CAPSCapstone Holding Corp
$ 3.36
(95.35%)
4.21M
XHLDTEN Holdings Inc
$ 2.2902
(63.59%)
81.71M
TNXPTonix Pharmaceuticals Holding Corporation
$ 33.2067
(44.19%)
3.9M
WLGSWang and Lee Group Inc
$ 0.710501
(-86.26%)
6.92M
ME23andMe Holding Company
$ 0.91
(-49.16%)
2.1M
RNAZTransCode Therapeutics Inc
$ 0.6995
(-37.54%)
9.86M
RCTRedCloud Holdings PLC
$ 4.6719
(-35.65%)
384.13k
UBXUNITY Biotechnology Inc
$ 1.19
(-34.79%)
1.23M
DMNDamon Inc
$ 0.0413
(10.72%)
164.56M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
$ 10.7207
(18.59%)
89.98M
MLGOMicroAlgo Inc
$ 5.5698
(121.02%)
89.93M
XHLDTEN Holdings Inc
$ 2.2902
(63.59%)
81.71M
TGLTreasure Global Inc
$ 0.1411
(28.27%)
67.44M